ArticleSmall science2023
iRGD-targeted Physalis Mottle Virus-like Nanoparticles for Targeted Cancer Delivery.
Article in Small science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Electrochemical Sensing of Doxorubicin in Breast Cancer Cells Based on Membrane-Permeation Strategy.Molecules (Basel, Switzerland) · 2026Article
- Engineering Extracellular Vesicles for Tumor Targeted Therapy: Source Optimization, Modification, and Clinical Application.International journal of nanomedicine · 2026Review
- STING Agonist-Loaded Physalis Mottle Virus-like Particles as a Potent Prophylactic for Metastatic Melanoma.ACS applied materials & interfaces · 2025Article
- Advances in targeted therapy for tumor with nanocarriers: A review.Materials today. Bio · 2025Review
- Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024Review
- Physalis Mottle Virus-Like Nanocarriers with Expanded Internal Loading Capacity.Bioconjugate chemistry · 2023Article
- Plant Virus Nanoparticles Combat Cancer.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Nanomedicine provides a promising platform for the molecular treatment of disease. An ongoing challenge in nanomedicine is the targeted delivery of intravenously administered nanoparticles to particular tissues, which is of special interest in cancer. In this study, we show that the conjugation of iRGD peptides, which specifically target tumor neovasculature, to the surface of Physalis mottle virus (PhMV)-like nanoparticles leads to rapid cellular uptake
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.